SCHEMBL3308555

SCHEMBL3308555

CCCCN(Cc1cc(OC)c(C(C)(C)C)cc1-c1ccc[nH]c1=O)S(C)(=O)=O

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.44
CYP3A4 P08684 4/20 0.42
KMT2A Q03164 2/20 0.35
PLEC Q15149 1/20 0.34
TSHR P16473 2/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 4/20 0.33
HPGD P15428 3/20 0.33
HSD17B10 Q99714 3/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
GAA P10253 1/20 0.33
MEN1 O00255 1/20 0.33
GLA P06280 1/20 0.33
ELANE P08246 3/20 0.32
CTSG P08311 1/20 0.32
ALPL P05186 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2354056 0.92 CYP3A4 (0.42) KDM4ECYP3A4KMT2AALDH1A1HPGD
SCHEMBL3314903 0.91 CYP3A4 (0.44) KDM4ECYP3A4KMT2ATSHRALDH1A1
SCHEMBL2352423 0.88 CYP3A4 (0.40) KDM4ECYP3A4ALDH1A1HPGDHSD17B10
SCHEMBL3308471 0.86 CYP3A4 (0.44) KDM4ECYP3A4ALDH1A1HPGDALPL
SCHEMBL3314215 0.84 CYP3A4 (0.45) KDM4ECYP3A4ALDH1A1HSD17B10ALPL
SCHEMBL3312623 0.83 CYP3A4 (0.44) CYP3A4ALPL
SCHEMBL3314664 0.81 CYP3A4 (0.43) KDM4ECYP3A4ALDH1A1HPGDALPL
SCHEMBL2352035 0.80 CYP3A4 (0.38) CYP3A4
SCHEMBL2362843 0.80 CYP3A4 (0.48) KDM4ECYP3A4ALDH1A1HPGDGAA
SCHEMBL11958301 0.79 CYP3A4 (0.41) KDM4ECYP3A4ALDH1A1HPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US claimed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B KDM4E 2438/4885CYP3A4 423/4885KMT2A 2306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.